Check out your Company Bowl for anonymous work chats.
LISTEN NOW: AI is only as good as the data that trains it. This is one of the lessons Dr. Lily Peng, Verily Director of Product Management, learned from her work on AI for diabetic retinopathy while at Google. The solution helped to screen the growing number of diabetic patients in India, showing how medical AI could benefit healthcare challenges. Hear more in NEJM Group's AI Grand Rounds podcast. #HealthTech #AIforHealth #DiabeticRetinopothy
The lack of diversity and representation in clinical trials continues to contribute to disparities in healthcare. Verily's Dr. Vindell Washington, Joe Franklin, Dr. Erich S. Huang, MD, PhD, Dr. Jessica Mega, MD MPH, and Dr. Amy Abernethy lay a foundation for how to approach DEI principles in study conduct in order to pursue more generalizable evidence that leads to better outcomes. Learn more in the paper “Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone,” published in American Society for Clinical Pharmacology & Therapeutics #PrecisionHealth #HealthEquity #BlackHistoryMonth #Verily
Women continue to be underrepresented in cardiovascular research. Project Baseline by Verily and the American Heart Association have joined forces to launch #ResearchGoesRed, an initiative to help close the gap and make sure women are represented. Learn more:
Did you see our Super Bowl ad? We’re so excited to see Dexcom’s #SuperBowl commercial debuting the U.S. launch of #DexcomG7! The new continuous glucose monitoring (CGM) system, developed in partnership with Verily, is small and discreet, but yet a powerful solution designed to help people with diabetes get personalized insights for better care management. Learn more:
In this STAT feature, Casey Ross goes in depth on Stephen Gillett, Verily's new CEO, providing an up close look into his leadership and highlighting where we're headed next as we work to bridge research and care. The piece really captures our journey and Stephen’s commitment to focus and achieving impact at scale. Join us! verily.com/careers
Today, we announced our expanded collaboration with Otsuka Pharmaceutical Companies (U.S.) on innovative clinical trials solutions to accelerate research in major depressive disorder (MDD). “These new recruitment and participant engagement capabilities offer the promise to include more participants in clinical research and to accelerate timelines to get treatments to patients faster,” said Amy Abernethy, President of Product Development & Chief Medical Officer at Verily. Read more:
Tune In: Season 2, Episode 5 of #ItsNotMagic is out now! Dr. Amy Abernethy is known for modernizing the FDA’s approach to big data. Now as Verily's President of Product Development and Chief Medical Officer, and a member of Sixth Street’s Scientific Advisory Board, she’s exploring approaches to real-world data and developing tools to bring advanced therapeutics to patients. Amy joins host David Stiepleman, as well as Sixth Street’s Vice Chairman, R. Martin Chavez, to discuss her contributions to transforming FDA processes and how today’s scientific advancements can lead toward improved public health outcomes. #Verily #PrecisionHealth
As we kick off the new year, we are excited to announce that Stephen Gillett officially begins his tenure as CEO of Verily today. Read about his vision to take Verily to new heights in our next chapter!
In the paper, “Diversity, Equity, and Inclusion in Clinical Research: a Path Towards Precision Health for Everyone” in American Society for Clinical Pharmacology & Therapeutics, Verily leaders share strategies to build more inclusion into clinical trials, make health more equitable, and advance #PrecisionHealth. Take a look:
90% of severe vision loss caused by diabetes is preventable with early detection and treatment strategies. Discover how Verily Retinal Service aims to expand access to quality eye screenings with our integrated platform, bringing solutions where they’re needed most to drive meaningful change for people with diabetes.
